– Generated Record Quarterly Net Revenue of $209.4 Million, Up 31% Year-over-Year – – Generated Record Quarterly Jornay PM® Net Revenue of $41.8 Million; Grew Prescriptions by 20% Year-over-Year – – Generated Record Quarterly Pain Portfolio Net Revenue of $167.6 Million, Up 11% Year-over-Year, with All Three Core Products Growing Year-over-Year – – Raised Full-Year 2025 Net Revenue Guidance to be in the Range of $775 to $785 Million and Adjusted EBITDA Guidance in the Range of $460 to $470 Million – – Ende ...

Leptomeningeal metastases disease session features novel treatments in the horizon, REYOBIQ™ and ReSPECT-LM, and future directions and needsHOUSTON, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, announces its participation at the 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting, Melanoma Research ...

LOWELL, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- MACOM Technology Solutions Holdings, Inc. (“MACOM”) (Nasdaq: MTSI), a leading supplier of semiconductor products, today announced its financial results for its fiscal fourth quarter and fiscal year ended October 3, 2025. Fourth Quarter Fiscal Year 2025 GAAP Results Revenue was $261.2 million, an increase of 30.1%, compared to $200.7 million in the previous year fiscal fourth quarter and an increase of 3.6% compared to $252.1 million in the prior fiscal quarte ...

VONORE, Tenn., Nov. 06, 2025 (GLOBE NEWSWIRE) -- MasterCraft Boat Holdings, Inc. (NASDAQ: MCFT) today announced financial results for its fiscal 2026 first quarter ended September 28, 2025. The overview, commentary, and results provided herein relate to our continuing operations, which consists of our MasterCraft and Pontoon segments. Overview: Net sales for the first quarter were $69.0 million, up $3.6 million, or 5.6%, from the comparable prior-year periodIncome from continuing operations was $3.7 million ...

New data builds on prior results, highlights LTI-03's differentiated approach, and supports the ongoing global Phase 2 RENEW trialAUSTIN, Texas, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, announced that a new preprint has been posted to medRxiv describing clinical and translational findings from an inhale ...

TROY, Mich., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Kelly (Nasdaq: KELYA, KELYB), a leading specialty talent solutions provider, today announced results for the third quarter of 2025. Q3 revenue of $935.0 million, down 9.9% year-over-year; excluding discrete U.S. federal government and large customer impacts, underlying revenue down approximately 2.0% year-over-yearUnderlying revenue reflects continued growth in the Education segment, a consistent rate of decline in the SET segment, and a modest decline in the E ...

FDA End-of-Phase 2 meeting for pilavapadin in DPNP to be held by year-end All IND-enabling studies of LX9851 for obesity completed and submitted to licensee Novo Nordisk Site initiation for SONATA-HCM Phase 3 study of sotagliflozin in both obstructive and non-obstructive HCM completed; enrollment completion on target for 2026 Additional data in support of potential resubmission of Zynquista for type 1 diabetes submitted to FDA Conference call and webcast at 8:30 am ET THE WOODLANDS, Texas, Nov. 06, 2025 ...

IND Submission for CR-001, a PD-1 x VEGF Bispecific Antibody, on Track for Fourth Quarter of 2025 to Support Initiation of Global Phase 1 Trial in Patients with Solid Tumors Advancing ADCs in the Pipeline, with IND Submission for CR-002 on Track for Mid-2026 WALTHAM, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced financial re ...

Achieved record levels of consolidated net revenue, gross profit and Adjusted EBITDA Net revenue in Q3 2025 increased by 9% quarter-over-quarter and 6% year-over-year Generated record-high net revenue in Israel, where PEACE NATURALS® remains the number one cannabis brand1 Industry-leading balance sheet with $824 million in total cash and cash equivalents and short-term investments TORONTO, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”), today annou ...

Solo Brands Accelerates Structural Cost Reduction to Match Current Demand Levels; Delivers $11 Million of Operating Cash in Q3, Marking Second Consecutive Quarter of Positive Cash FlowGRAPEVINE, Texas, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Solo Brands, Inc. (NYSE: SBDS)(1) (“Solo Brands” or “the Company”) a leading portfolio of lifestyle brands (Solo Stove, Chubbies, Isle and Oru) that are redefining the outdoor and apparel industries, today announced its financial results for the three and nine months ended Se ...